| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005733793 |
| P356 | DOI | 10.2165/11584600-000000000-00000 |
| P698 | PubMed publication ID | 21142277 |
| P5875 | ResearchGate publication ID | 49668437 |
| P50 | author | Jason Madan | Q56528817 |
| Jonathan Karnon | Q56954843 | ||
| John Edmunds | Q87928638 | ||
| Richard G White | Q39048231 | ||
| P2093 | author name string | Rosa Legood | |
| Anna M Foss | |||
| Tazio Vanni | |||
| P2860 | cites work | The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women | Q50638852 |
| Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis | Q50770674 | ||
| The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? | Q51113940 | ||
| A hybrid cohort individual sampling natural history model of age-related macular degeneration: assessing the cost-effectiveness of screening using probabilistic calibration. | Q51127005 | ||
| Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. | Q51862683 | ||
| Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. | Q52024329 | ||
| Multiparameter Calibration of a Natural History Model of Cervical Cancer | Q57089398 | ||
| The Wisconsin Breast Cancer Epidemiology Simulation Model | Q79220380 | ||
| Calibration of disease simulation model using an engineering approach | Q84832095 | ||
| Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period | Q28392207 | ||
| Calibration methods used in cancer simulation models and suggested reporting guidelines | Q28749665 | ||
| Estimation of markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration | Q31017619 | ||
| Bayesian inference of hospital-acquired infectious diseases and control measures given imperfect surveillance data | Q31056266 | ||
| Confronting models with data | Q31114314 | ||
| An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. | Q33387534 | ||
| Estimating progression rates for human papillomavirus infection from epidemiological data | Q33467330 | ||
| Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales | Q33572897 | ||
| Calibration of disease simulation model using an engineering approach | Q33926840 | ||
| Artificial neural networks: opening the black box. | Q34223374 | ||
| Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme | Q35656655 | ||
| Review of guidelines for good practice in decision-analytic modelling in health technology assessment | Q35884295 | ||
| Option appraisal of population-based colorectal cancer screening programmes in England | Q35929500 | ||
| Evidence synthesis, parameter correlation and probabilistic sensitivity analysis | Q36359124 | ||
| Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination | Q36404994 | ||
| Recent developments in decision-analytic modelling for economic evaluation | Q36635487 | ||
| Economic evaluation of human papillomavirus vaccination in the United Kingdom | Q36818045 | ||
| What is the achievable effectiveness of the India AIDS Initiative intervention among female sex workers under target coverage? Model projections from southern India | Q36928589 | ||
| A review and critique of modelling in prioritising and designing screening programmes. | Q37010504 | ||
| The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. | Q37177562 | ||
| Cost-utility analysis of screening high-risk groups for anal cancer. | Q37193207 | ||
| Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). | Q37427905 | ||
| Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh? | Q39009039 | ||
| Uncertainty and validation of health economic decision models | Q39137032 | ||
| Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty | Q40245291 | ||
| Cost-effectiveness of HPV 16, 18 vaccination in Brazil | Q44396284 | ||
| Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria | Q45309251 | ||
| Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy | Q50129780 | ||
| The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods | Q50192553 | ||
| P433 | issue | 1 | |
| P921 | main subject | model calibration | Q95753510 |
| P304 | page(s) | 35-49 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Calibrating models in economic evaluation: a seven-step approach | |
| P478 | volume | 29 |
| Q58803158 | A dynamic Bayesian Markov model for health economic evaluations of interventions in infectious disease |
| Q57515329 | Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models |
| Q34628837 | Accounting for costs, QALYs, and capacity constraints: using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services |
| Q38936428 | Bayesian Methods for Calibrating Health Policy Models: A Tutorial |
| Q33565799 | Brief introductory guide to agent-based modeling and an illustration from urban health research |
| Q38766423 | Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria |
| Q45309251 | Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria |
| Q36843345 | Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial |
| Q39553755 | Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country |
| Q39638320 | Changing Cycle Lengths in State-Transition Models: Challenges and Solutions |
| Q91863526 | Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study |
| Q90788888 | Cost effectiveness of dengue vaccination following pre-vaccination serological screening in Sri Lanka |
| Q39027269 | Cost-effectiveness analysis of 3-D computerized tomography colonography versus optical colonoscopy for imaging symptomatic gastroenterology patients |
| Q36701872 | Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease |
| Q48168966 | Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension |
| Q54962623 | Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. |
| Q40225577 | DOES ONE SIZE FIT ALL? COST UTILITY ANALYSES OF ALTERNATIVE MAMMOGRAPHIC FOLLOW-UP SCHEDULES, BY RISK OF RECURRENCE. |
| Q92181796 | Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities |
| Q39051954 | Economic evaluations with agent-based modelling: an introduction |
| Q39553749 | Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. |
| Q90452923 | Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder |
| Q98216322 | Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis |
| Q92057792 | Estimating the total incidence of global childhood cancer: a simulation-based analysis |
| Q90608461 | Estimation of Eating Disorders Prevalence by Age and Associations With Mortality in a Simulated Nationally Representative US Cohort |
| Q94585008 | Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection |
| Q36991723 | Evidence synthesis for decision making 5: the baseline natural history model |
| Q92293906 | Global childhood cancer survival estimates and priority-setting: a simulation-based analysis |
| Q34778132 | Identifying best-fitting inputs in health-economic model calibration: a Pareto frontier approach |
| Q52640420 | Implementing parallel spreadsheet models for health policy decisions: The impact of unintentional errors on model projections. |
| Q46659871 | Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches |
| Q47613804 | MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER. |
| Q36602310 | Mechanical Thrombectomy in Patients With Acute Ischemic Stroke: A Health Technology Assessment |
| Q37066825 | Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis |
| Q36615123 | Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community |
| Q39667385 | Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives |
| Q38086133 | Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases : a review and suggested reporting framework. |
| Q57589510 | Modeling Using Discrete Event Simulation |
| Q33969384 | Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India |
| Q36286729 | Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small-cell lung cancer |
| Q34786520 | Modelling the transmission of healthcare associated infections: a systematic review |
| Q37467507 | Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity |
| Q91689068 | Nonidentifiability in Model Calibration and Implications for Medical Decision Making |
| Q34978379 | Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings |
| Q90264893 | Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes? |
| Q55397815 | Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening. |
| Q92158358 | Simulation models for transmission of health care-associated infection: A systematic review |
| Q38620960 | Societal and Family Lifetime Cost of Dementia: Implications for Policy |
| Q35568922 | Systematic review of model-based cervical screening evaluations |
| Q39471203 | The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe |
| Q88420600 | Turning High-Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long-Term Care |
| Q35070944 | Validation and calibration of a computer simulation model of pediatric HIV infection |
| Q30239838 | Validation and calibration of structural models that combine information from multiple sources |
| Q37340602 | What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia |
Search more.